Skip to content

Study · Animal study (in vivo) · mouse · 2021

8 results

Liraglutide Attenuates Myocardial Fibrosis via Inhibition of AT1R-Mediated ROS Production in Hypertensive Mice.

Chen P, Yang F, Wang W, Li X, Liu D, Zhang Y, Yin G, Lv F, Guo Z, Mehta JL, Wang X

Journal of cardiovascular pharmacology and therapeutics20 Jul 2020Cited by 28 (Europe PMC)

PMID32686479 (opens in a new tab)DOI10.1177/1074248420942007 (opens in a new tab)PepBankPUB-32686479
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Ang II-induced hypertensive mice, liraglutide reduced blood pressure.

    In plain wordsIn mice with induced high blood pressure, liraglutide lowered blood pressure.

    Peptide
    Liraglutide
    Outcome
    DecreaseBlood pressure
    Study

    mousen: not reported in source

    Ang II-induced hypertensive C57BL/6 mice
    Comparator
    Hypertensive mice given vehicle
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    400 μg/kg·dayAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide reduced BP and blood sugar but did not affect the body weight of the hypertensive mice.
    3 context sentences
    Summary · context
    C57BL/6 mice (3-month old) were randomly divided into control, hypertension, and hypertension + liraglutide groups.
    Summary · context
    The hypertensive state was created by infusion of Ang II (100 ng/kg·min) for 4 weeks through subcutaneously implanted osmotic pumps.
    Summary · context
    Mice were also given vehicle or liraglutide (400 μg/kg·day).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In Ang II-induced hypertensive mice, liraglutide reduced blood sugar.

    In plain wordsIn mice with induced high blood pressure, liraglutide lowered blood sugar.

    Peptide
    Liraglutide
    Outcome
    DecreaseBlood sugar
    Study

    mousen: not reported in source

    Ang II-induced hypertensive C57BL/6 mice
    Comparator
    Hypertensive mice given vehicle
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    400 μg/kg·dayAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide reduced BP and blood sugar but did not affect the body weight of the hypertensive mice.
    3 context sentences
    Summary · context
    C57BL/6 mice (3-month old) were randomly divided into control, hypertension, and hypertension + liraglutide groups.
    Summary · context
    The hypertensive state was created by infusion of Ang II (100 ng/kg·min) for 4 weeks through subcutaneously implanted osmotic pumps.
    Summary · context
    Mice were also given vehicle or liraglutide (400 μg/kg·day).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In Ang II-induced hypertensive mice, liraglutide did not affect body weight.

    In plain wordsIn mice with induced high blood pressure, liraglutide did not change body weight.

    Peptide
    Liraglutide
    Outcome
    No significant changeBody weight
    Study

    mousen: not reported in source

    Ang II-induced hypertensive C57BL/6 mice
    Comparator
    Hypertensive mice given vehicle
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    400 μg/kg·dayAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide reduced BP and blood sugar but did not affect the body weight of the hypertensive mice.
    3 context sentences
    Summary · context
    C57BL/6 mice (3-month old) were randomly divided into control, hypertension, and hypertension + liraglutide groups.
    Summary · context
    The hypertensive state was created by infusion of Ang II (100 ng/kg·min) for 4 weeks through subcutaneously implanted osmotic pumps.
    Summary · context
    Mice were also given vehicle or liraglutide (400 μg/kg·day).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In Ang II-induced hypertensive mice, liraglutide inhibited collagen accumulation in the heart.

    In plain wordsIn mice with induced high blood pressure, liraglutide reduced scar-like collagen build-up in the heart.

    Peptide
    Liraglutide
    Outcome
    DecreaseMyocardial collagen accumulation
    Study

    mousen: not reported in source

    Ang II-induced hypertensive C57BL/6 mice
    Comparator
    Hypertensive mice given vehicle
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    400 μg/kg·dayAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide also inhibited collagen accumulation, AT1R expression, and ROS generation in the hearts of the hypertensive mice.
    3 context sentences
    Summary · context
    C57BL/6 mice (3-month old) were randomly divided into control, hypertension, and hypertension + liraglutide groups.
    Summary · context
    The hypertensive state was created by infusion of Ang II (100 ng/kg·min) for 4 weeks through subcutaneously implanted osmotic pumps.
    Summary · context
    Mice were also given vehicle or liraglutide (400 μg/kg·day).
  5. 05AnimalAnimal study (in vivo)Mechanism

    In Ang II-induced hypertensive mice, liraglutide inhibited AT1R expression in the heart.

    In plain wordsIn mice with induced high blood pressure, liraglutide lowered the level of the AT1R receptor in the heart.

    Peptide
    Liraglutide
    Outcome
    DecreaseMyocardial AT1R expression
    Study

    mousen: not reported in source

    Ang II-induced hypertensive C57BL/6 mice
    Comparator
    Hypertensive mice given vehicle
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    400 μg/kg·dayAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide also inhibited collagen accumulation, AT1R expression, and ROS generation in the hearts of the hypertensive mice.
    3 context sentences
    Summary · context
    C57BL/6 mice (3-month old) were randomly divided into control, hypertension, and hypertension + liraglutide groups.
    Summary · context
    The hypertensive state was created by infusion of Ang II (100 ng/kg·min) for 4 weeks through subcutaneously implanted osmotic pumps.
    Summary · context
    Mice were also given vehicle or liraglutide (400 μg/kg·day).
  6. 06AnimalAnimal study (in vivo)Mechanism

    In Ang II-induced hypertensive mice, liraglutide inhibited reactive oxygen species generation in the heart.

    In plain wordsIn mice with induced high blood pressure, liraglutide reduced reactive oxygen species in the heart.

    Peptide
    Liraglutide
    Outcome
    DecreaseMyocardial reactive oxygen species
    Study

    mousen: not reported in source

    Ang II-induced hypertensive C57BL/6 mice
    Comparator
    Hypertensive mice given vehicle
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    400 μg/kg·dayAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide also inhibited collagen accumulation, AT1R expression, and ROS generation in the hearts of the hypertensive mice.
    3 context sentences
    Summary · context
    C57BL/6 mice (3-month old) were randomly divided into control, hypertension, and hypertension + liraglutide groups.
    Summary · context
    The hypertensive state was created by infusion of Ang II (100 ng/kg·min) for 4 weeks through subcutaneously implanted osmotic pumps.
    Summary · context
    Mice were also given vehicle or liraglutide (400 μg/kg·day).
  7. 07LabIn vitro (cells)Mechanism

    In cultured mouse cardiac fibroblasts, pretreatment with liraglutide markedly inhibited Ang II-induced reactive oxygen species production.

    In plain wordsIn cells, liraglutide pretreatment strongly reduced reactive oxygen species caused by Ang II.

    Peptide
    Liraglutide
    Outcome
    DecreaseAng II-induced ROS production in cardiac fibroblasts
    Study

    mousen: not reported in source

    Isolated mouse cardiac fibroblasts stimulated with Ang II
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    300 nM/L · 3 hours pretreatment before Ang IIAs given in this study (mouse).

    Source sentences

    Summary
    In in vitro studies, pretreatment with liraglutide and losartan (as control) markedly inhibited Ang II-induced ROS production and collagen expression in the cultured cardiac fibroblasts.
    1 context sentence
    Summary · context
    To further elucidate the mechanisms of fibrosis, mouse cardiac fibroblasts were isolated and treated with liraglutide (300 nM/L) or losartan (10 μM) for 3 hours, followed by Ang II (10-7 M) for additional 12 hours.
  8. 08LabIn vitro (cells)Mechanism

    In cultured mouse cardiac fibroblasts, pretreatment with liraglutide markedly inhibited Ang II-induced collagen expression.

    In plain wordsIn cells, liraglutide pretreatment strongly reduced collagen production caused by Ang II.

    Peptide
    Liraglutide
    Outcome
    DecreaseAng II-induced collagen expression in cardiac fibroblasts
    Study

    mousen: not reported in source

    Isolated mouse cardiac fibroblasts stimulated with Ang II
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    300 nM/L · 3 hours pretreatment before Ang IIAs given in this study (mouse).

    Source sentences

    Summary
    In in vitro studies, pretreatment with liraglutide and losartan (as control) markedly inhibited Ang II-induced ROS production and collagen expression in the cultured cardiac fibroblasts.
    1 context sentence
    Summary · context
    To further elucidate the mechanisms of fibrosis, mouse cardiac fibroblasts were isolated and treated with liraglutide (300 nM/L) or losartan (10 μM) for 3 hours, followed by Ang II (10-7 M) for additional 12 hours.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.